674 related articles for article (PubMed ID: 17601632)
21. Weekly epoetin beta maintains haemoglobin levels and improves quality of life in patients with non-myeloid malignancies receiving chemotherapy.
Suzuki Y; Tokuda Y; Fujiwara Y; Minami H; Ohashi Y; Saijo N
Jpn J Clin Oncol; 2008 Mar; 38(3):214-21. PubMed ID: 18296425
[TBL] [Abstract][Full Text] [Related]
22. Is epoetin alfa a treatment option for chemotherapy-related anemia in children?
Büyükpamukçu M; Varan A; Kutluk T; Akyüz C
Med Pediatr Oncol; 2002 Oct; 39(4):455-8. PubMed ID: 12203663
[TBL] [Abstract][Full Text] [Related]
23. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.
Leyland-Jones B; Semiglazov V; Pawlicki M; Pienkowski T; Tjulandin S; Manikhas G; Makhson A; Roth A; Dodwell D; Baselga J; Biakhov M; Valuckas K; Voznyi E; Liu X; Vercammen E
J Clin Oncol; 2005 Sep; 23(25):5960-72. PubMed ID: 16087945
[TBL] [Abstract][Full Text] [Related]
24. Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies.
Straus DJ; Testa MA; Sarokhan BJ; Czuczman MS; Tulpule A; Turner RR; Riggs SA
Cancer; 2006 Oct; 107(8):1909-17. PubMed ID: 16977654
[TBL] [Abstract][Full Text] [Related]
25. Extended epoetin alfa dosing in chronic kidney disease patients: a retrospective review.
Germain M; Ram CV; Bhaduri S; Tang KL; Klausner M; Curzi M
Nephrol Dial Transplant; 2005 Oct; 20(10):2146-52. PubMed ID: 15985516
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
[TBL] [Abstract][Full Text] [Related]
27. Effects of epoetin-alpha on quality of life of cancer patients with solid tumors receiving chemotherapy.
Christodoulou C; Dafni U; Aravantinos G; Koutras A; Samantas E; Karina M; Janinis J; Papakostas P; Skarlos D; Kalofonos HP; Fountzilas G
Anticancer Res; 2009 Feb; 29(2):693-702. PubMed ID: 19331224
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of epoetin supplemented with oral iron in patients with solid malignancies and chronic anemia not receiving anticancer treatment.
Mystakidou K; Kalaidopoulou O; Katsouda E; Parpa E; Kouskouni E; Chondros C; Tsiatas ML; Vlahos L
Anticancer Res; 2005; 25(5):3495-500. PubMed ID: 16101168
[TBL] [Abstract][Full Text] [Related]
29. A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer scheduled to receive first-line chemotherapy.
Crawford J; Robert F; Perry MC; Belani C; Williams D;
J Thorac Oncol; 2007 Mar; 2(3):210-20. PubMed ID: 17410044
[TBL] [Abstract][Full Text] [Related]
30. The impact of weekly dosing of epoetin alfa on the haematological parameters and on the quality of life of anaemic cancer patients.
Heras P; Argyriou AA; Papapetropoulos S; Karagiannis S; Argyriou K; Mitsibounas D
Eur J Cancer Care (Engl); 2005 May; 14(2):108-12. PubMed ID: 15842457
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial.
Grote T; Yeilding AL; Castillo R; Butler D; Fishkin E; Henry DH; DeLeo M; Fink K; Sullivan DJ
J Clin Oncol; 2005 Dec; 23(36):9377-86. PubMed ID: 16361638
[TBL] [Abstract][Full Text] [Related]
32. Recombinant human erythropoietin beta therapy: an effective strategy to reduce transfusion requirement in children receiving anticancer treatment.
Corapcioglu F; Aksu G; Basar EZ; Demirel A; Oncel S; Mutlu A
Pediatr Hematol Oncol; 2008 Sep; 25(6):509-21. PubMed ID: 18728970
[TBL] [Abstract][Full Text] [Related]
33. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study.
Aapro M; Leonard RC; Barnadas A; Marangolo M; Untch M; Malamos N; Mayordomo J; Reichert D; Pedrini JL; Ukarma L; Scherhag A; Burger HU
J Clin Oncol; 2008 Feb; 26(4):592-8. PubMed ID: 18235117
[TBL] [Abstract][Full Text] [Related]
34. Initiation of epoetin-alpha therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy: an open-label, multicenter study with randomized and nonrandomized treatment arms.
Glaspy JA; Charu V; Luo D; Moyo V; Kamin M; Wilhelm FE
Cancer; 2009 Mar; 115(5):1121-31. PubMed ID: 19170225
[TBL] [Abstract][Full Text] [Related]
35. Once weekly recombinant human erythropoietin treatment for cancer-induced anemia in children with acute lymphoblastic leukemia receiving maintenance chemotherapy: a randomized case-controlled study.
Abdelrazik N; Fouda M
Hematology; 2007 Dec; 12(6):533-41. PubMed ID: 17852440
[TBL] [Abstract][Full Text] [Related]
36. Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: Results of a multicenter randomised controlled trial.
Savonije JH; van Groeningen CJ; van Bochove A; Honkoop AH; van Felius CL; Wormhoudt LW; Giaccone G
Eur J Cancer; 2005 Jul; 41(11):1560-9. PubMed ID: 15953714
[TBL] [Abstract][Full Text] [Related]
37. Clinical experience with epoetin alfa in the management of hemoglobin levels in orthopedic surgery and cancer. Implications for use in gynecologic surgery.
Stovall TG
J Reprod Med; 2001 May; 46(5 Suppl):531-8. PubMed ID: 11396387
[TBL] [Abstract][Full Text] [Related]
38. Role of epoetin in the management of anaemia in patients with lung cancer.
Morère JF
Lung Cancer; 2004 Nov; 46(2):149-56. PubMed ID: 15474662
[TBL] [Abstract][Full Text] [Related]
39. Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy.
Razzouk BI; Hord JD; Hockenberry M; Hinds PS; Feusner J; Williams D; Rackoff WR
J Clin Oncol; 2006 Aug; 24(22):3583-9. PubMed ID: 16877725
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]